Silence Therapeutics plc

Report Publication Announcement • Sep 2, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5632Q

Silence Therapeutics PLC

02 September 2014

2 September 2014

Silence Therapeutics plc

Board change

Silence Therapeutics plc, AIM: SLN, announces that due to family commitments, Chief Operating Officer Annie Cheng has resigned from the Board with effect from today, ahead of moving back to New York early next year.

Ali Mortazavi, CEO of Silence Therapeutics, said:

"Annie has made a valuable contribution to our strategic direction. She will work closely with the Company over the coming months, with a view to a consulting role when she is back in the US."

Enquiries:

Silence Therapeutics plc	+44 (0)20 3700 9711
Ali Mortazavi, CEO
Timothy Freeborn, Finance Director
Rozi Morris, Communications Manager
Canaccord Genuity Limited	+44 (0)20 7523 8350
Lucy Tilley/Dr Julian Feneley/Henry Fitzgerald-O'Connor

About Silence Therapeutics plc    (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNA interference (RNAi) or 'gene silencing' platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.

Silence is one of only a handful of listed companies globally which has human validated RNA delivery technology.  Its platform is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. Silence's RNAi platform has been used in three Phase 2 clinical trials, two awaiting results. It also has a robust IP estate protecting its proprietary technology.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAQKDDQABKDFCK